NIVF vs. ACON, ATIP, VSEE, DHAC, OTRK, BACK, BTTX, UPHL, OPGN, and ACONW
Should you be buying NewGenIvf Group stock or one of its competitors? The main competitors of NewGenIvf Group include Aclarion (ACON), ATI Physical Therapy (ATIP), VSee Health (VSEE), Digital Health Acquisition (DHAC), Ontrak (OTRK), IMAC (BACK), Better Therapeutics (BTTX), UpHealth (UPHL), OpGen (OPGN), and Aclarion (ACONW). These companies are all part of the "healthcare" industry.
NewGenIvf Group vs. Its Competitors
Aclarion (NASDAQ:ACON) and NewGenIvf Group (NASDAQ:NIVF) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.
Aclarion currently has a consensus price target of $11,758.50, suggesting a potential upside of 161,528.87%. Given Aclarion's stronger consensus rating and higher possible upside, equities analysts plainly believe Aclarion is more favorable than NewGenIvf Group.
7.5% of Aclarion shares are owned by institutional investors. Comparatively, 66.2% of NewGenIvf Group shares are owned by institutional investors. 0.8% of Aclarion shares are owned by insiders. Comparatively, 31.8% of NewGenIvf Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Aclarion had 2 more articles in the media than NewGenIvf Group. MarketBeat recorded 4 mentions for Aclarion and 2 mentions for NewGenIvf Group. NewGenIvf Group's average media sentiment score of 0.50 beat Aclarion's score of 0.40 indicating that NewGenIvf Group is being referred to more favorably in the news media.
Aclarion has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Comparatively, NewGenIvf Group has a beta of -0.09, meaning that its share price is 109% less volatile than the S&P 500.
NewGenIvf Group has higher revenue and earnings than Aclarion.
NewGenIvf Group has a net margin of 0.00% compared to Aclarion's net margin of -11,238.59%. NewGenIvf Group's return on equity of 0.00% beat Aclarion's return on equity.
Summary
NewGenIvf Group beats Aclarion on 8 of the 13 factors compared between the two stocks.
Get NewGenIvf Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for NIVF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NIVF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NewGenIvf Group Competitors List
Related Companies and Tools
This page (NASDAQ:NIVF) was last updated on 9/5/2025 by MarketBeat.com Staff
